Eli Lilly Again Boosts FY25 Outlook – Update
While reporting financial results for the third quarter on Thursday, drugmaker Eli Lilly and Co. (LLY) raised its earnings, adjusted earnings and revenue guidance for the full-year 2025, primarily driven by strong underlying business performance across the portfolio a.